Literature DB >> 10589911

Treatment of tularemia with fluoroquinolones: two cases and review.

A P Limaye1, C J Hooper.   

Abstract

Streptomycin, gentamicin, and tetracycline are currently considered the antimicrobials of choice for the treatment of tularemia. Preliminary data suggest that quinolones may be effective alternative agents; however, clinical experience is limited, and their role in treating severe disease is uncertain. We recently treated two acutely ill immunocompromised patients who had presumed "atypical" pneumonia with levofloxacin. Both patients had an excellent clinical response and were diagnosed with tularemia only when blood cultures subsequently yielded Francisella tularensis. Neither patient relapsed during 12 months of follow-up. Including our two cases, a total of 10 cases of tularemia treated with quinolones have been reported. In all 10 cases, a favorable clinical response was documented, and no relapses occurred. We conclude that the quinolones appear promising for the treatment of even severe tularemia, and they should be considered efficacious alternative agents for patients who do not require parenteral therapy or are intolerant of more standard treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589911     DOI: 10.1086/520458

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.

Authors:  Michael A Pammit; Varija N Budhavarapu; Erin K Raulie; Karl E Klose; Judy M Teale; Bernard P Arulanandam
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Francisella tularensis bacteremia.

Authors:  X Haristoy; A Lozniewski; C Tram; D Simeon; L Bevanger; C Lion
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

Review 3.  Tularemia: a rare cause of neck mass, evaluation of 33 patients.

Authors:  Sedat Cağlı; Alperen Vural; Onur Sönmez; Imdat Yüce; Ercihan Güney
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-08-04       Impact factor: 2.503

4.  Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).

Authors:  Michelle Nelson; Mark S Lever; Rachel E Dean; Peter C Pearce; Daniel J Stevens; Andrew J H Simpson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

6.  Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.

Authors:  Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner
Journal:  Biomaterials       Date:  2018-10-16       Impact factor: 12.479

Review 7.  Tick-borne infections in children: epidemiology, clinical manifestations, and optimal management strategies.

Authors:  Steven C Buckingham
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 8.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.

Authors:  Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.

Authors:  Kathleen England; Christopher am Ende; Hao Lu; Todd J Sullivan; Nicole L Marlenee; Richard A Bowen; Susan E Knudson; Dennis L Knudson; Peter J Tonge; Richard A Slayden
Journal:  J Antimicrob Chemother       Date:  2009-09-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.